MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12185-019-02613-1

Медицинская библиотека · International journal of hematology · 2019

Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

Kizaki Masahiro, Takahashi Naoto, Iriyama Noriyoshi, Okamoto Shinichiro, Ono Takaaki, Usui Noriko, Inokuchi Koiti, Nakaseko Chiaki, Kurokawa Mineo, Sumi Masahiko, Nakamura Fumihiko, Kawaguchi Tatsuya, Suzuki Ritsuro, Yamamoto Kazuhito, Ohnishi Kazunori, Matsumura Itaru, Naoe Tomoki, New TARGET investigators

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

We report the results of a multicenter observational study using the New TARGET system, in which the effectiveness and safety of tyrosine kinase inhibitors (TKIs) were evaluated in newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. A total of 506 patients were enrolled between April 2010 and March 2013. Median age was 56 (range 18-92) years; 35% of patients were females. As the first-line therapy, 139 (27.9%), 169 (33.9%) and 144 (28.9%) patients were treated with imatinib, nilotinib, and dasatinib, respectively. Five-year progression-free survival (PFS) and overall survival (OS) were 93.8% and 94.5%, respectively. The OS curve was significantly superior for patients treated with second-generation TKIs than imatinib (P = 0.0068), and an early molecular response (EMR) at 3 months (BCR-ABL1 < 10%) was detected in 328 of 377 patients evaluated for molecular response. The PFS curve was significantly superior for patients with EMR than without (P < 0.0001). Although 12 patients experienced vascular adverse events, no new safety issues were observed in patients with adverse events. The results of this observational study demonstrated that treating newly diagnosed CML-CP patients with TKI results in satisfactory and reliable outcomes.

Для цитирования: Kizaki Masahiro, Takahashi Naoto, Iriyama Noriyoshi, Okamoto Shinichiro, Ono Takaaki, Usui Noriko, Inokuchi Koiti, Nakaseko Chiaki, Kurokawa Mineo, Sumi Masahiko, Nakamura Fumihiko, Kawaguchi Tatsuya, Suzuki Ritsuro, Yamamoto Kazuhito, Ohnishi Kazunori, Matsumura Itaru, Naoe Tomoki, New TARGET investigators. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.. International journal of hematology. 2019. DOI: 10.1007/s12185-019-02613-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.